ETIOSARC study : environmental aetiology of sarcomas from a French prospective multicentric population-based case–control study—study protocol

Autor: Aude Lacourt, Alain Monnereau, Brice Amadéo, Céline Gramond, Sandrine Plouvier, Jean-Yves Blay, Jean-Michel Coindre, Gonzague de Pinieux, François Gouin, Antoine Italiano, Axel Le Cesne, François Le Loarer, Isabelle Pellegrin, Nicolas Penel, Maud Toulmonde, Françoise Ducimetière, A Lacourt, B Amadéo, C Gramond, E Marrer, S Plouvier, I Baldi, S Bara, C Bazille, J Y Blay, E Bompas, L Chaigneau, M C Chateau, J M Coindre, G Coureau, D Cupissol, T D’Almeida, G Defossez, P Delafosse, C Delcambre Lair, G De Pinieux, A Di Marco, T Fabre, F Fiorenza, J P Ghnassia, F Gouin, A V Guizard, A Italiano, J E Kurtz, V Lebrun-Ly, A Le Cesne, F Le Loarer, L R Le Nail, C Maynou, G Missenard, F Molinié, A Monnereau, A Moreau, N Penel, D Ranchère-Vince, I Ray-Coquard, Y M Robin, P Terrier, M Toulmonde, B Tretarre, M Velten, A S Woronoff, F Ducimetière, S Mathoulin-Pélissier

Publikováno v: BMJ Open, Vol 9, Iss 6 (2019)

IntroductionSarcomas are rare tumours of connective tissue. The exact overall incidence of sarcomas is unknown due to diagnostic difficulties and the various histological subtypes (over 80 subtypes). However, the apparent increasing incidence of sarc

Externí odkaz: https://doaj.org/article/0cb29a20a5934328a2555f7ad06d96b7

Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer:phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis

Autor: S I, Labidi-Galy, M, Rodrigues, J L, Sandoval, J E, Kurtz, F, Heitz, A M, Mosconi, I, Romero, U, Denison, S, Nagao, I, Vergote, G, Parma, T J, Nøttrup, E, Rouleau, G, Garnier, A, El-Balat, C, Zamagni, C, Martín-Lorente, E, Pujade-Lauraine, A, Fiévet, I L, Ray-Coquard

Publikováno v: Labidi-Galy, S I, Rodrigues, M, Sandoval, J L, Kurtz, J E, Heitz, F, Mosconi, A M, Romero, I, Denison, U, Nagao, S, Vergote, I, Parma, G, Nøttrup, T J, Rouleau, E, Garnier, G, El-Balat, A, Zamagni, C, Martín-Lorente, C, Pujade-Lauraine, E, Fiévet, A & Ray-Coquard, I L 2023, ' Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer : phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis ', Annals of Oncology, vol. 34, no. 2, pp. 152-162 . https://doi.org/10.1016/j.annonc.2022.11.003

BACKGROUND: In the phase III PAOLA-1 study, the addition of maintenance olaparib to bevacizumab in patients with newly diagnosed high-grade ovarian cancer (HGOC) resulted in prolonged progression-free survival (PFS), particularly for homologous recom

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7238bd7941a935684f35290251f1a332
https://curis.ku.dk/ws/files/338357926/1_s2.0_S0923753422047330_main.pdf

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Prise en charge médicale de la récidive du cancer épithélial de l'ovaire: Medical management of recurrent epithelial ovarian cancer

Autor: Patricia, Pautier, Thibault de la, Motte-Rouge, Fabrice, Lécuru, Jean-Marc, Classe, Gwenaël, Ferron, Anne, Floquet, J E, Kurtz, Gilles, Freyer, Anne-Claire, Hardy-Bessard

Publikováno v: Bulletin du cancer. 108(9S1)

The panel of therapeutic options available for medical treatment of relapsed ovarian cancer increased over the last years. In late, platinum-sensitive relapse, standard treatment remains platinum-based polychemotherapy. The choice between bevacizumab

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::b7b0ab193e9f7c8a4a88ba87ebb97785
https://pubmed.ncbi.nlm.nih.gov/34955159

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.